Login   |   Register   
Address 1 :
Address 2 :
Title : Mr.
First Name : DANDA
Last Name : CHAPAGAI
University/Institution : University of South Carolina
Phone # : 5612359426
Email ID : chapagaidanda@gmail.com
City : Columbia
Country : United States
State : South carolina
Zipcode : 29210
Department : Drug Discovery and Biomedical Sciences
Company Name :
Area of Research
Area of Expertise
Molecular pharmacology, mechanism of action, in vivo pharmacology, chemical genetics approach
Brief Description of Research Interest :

Mr. Danda Chapagai is a 5th year PhD student at Drug Discovery and Biomedical Sciences at the University of South Carolina (USC). Danda received his MS degree from East Tennessee State University (ETSU). His research interest include cell signaling and drug design. In his Master dissertation at ETSU, he characterized a putative lipid transfer protein involved in defense signaling. In his current doctoral dissertation research at USC, he is working on development and mechanistic study of novel inhibitors of the Polo Like Kinase 1 (PLK1) Polo Box Domain (PBD) for cancer therapy. PLK1 inhibitors targeting catalytic domain have advanced to clinical trials but not demonstrated convincing efficacy. Targeting the PBD of PLK1 offers an attractive alternative to pursue PLK1 inhibition. His dissertation presents small molecule inhibitors targeting the PBD of PLK1 and non-ATP competitive are a potentially compelling alternative to catalytic-based inhibitors with novel mechanism of actions and drug-like properties.

Representative Publications :

1.    Danda Chapagai,Guru Ramamoorthy, Sandra Craig, Merissa Baxter, Elmar Nurmemmedov, Campbell McInnes and Michael D. Wyatt, “Non-Peptidic inhibitors of the PLK1 Polo Box Domain block TCTP phosphorylation, induce its degradation and target resistant cells” Journal of Medicinal Chemistry. 2021 64(14):9916-9925. https://pubmed.ncbi.nlm.nih.gov/34210138/

2.    Danda Chapagai, Campbell McInnes and Michael D. Wyatt, “Differential changes in PLK1 conformation and intracellular stability induced by ATP competitive and novel non-competitive abbapolin inhibitors”. (Under Review)

3.    Danda Chapagai, Guru Ramamoorthy, Jessy Varghese, Merissa Baxter, Elmar Nurmemmedov, Campbell McInnes and Michael D. Wyatt, “Novel small molecule inhibitor targeting the PBD of PLK1 for the prostate cancer therapy”. (Under Review)

4.     Sandra Craig, Merissa Baxter, Danda Chapagai, Elmar Nurmemmedov, Diego Altomare, Michael D. Wyatt, Campbell McInnes, “Structure-activityand mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE”. European Journal of Medicinal Chemistry, 2021, 227:113926. https://pubmed.ncbi.nlm.nih.gov/34735919/

5.     Merissa Baxter, Danda Chapagai, Sandra Craig,Cecilia Hurtado, Jessy Varghese, Elmar Nurmemmedov, Michael D Wyatt, Campbell McInnes, “Peptidomimetic Polo-Box targeted inhibitors that engage PLK1 in tumor cells and are selective against the PLK3 tumor suppressor” ChemMedChem2020,15 (12), 1058–1066. https://doi.org/10.1002/cmdc.202000137

6.     Kumar,Dhirendra, Imdadul Haq, Danda Chapagai, Diwaker Tripathi, David Donald, Mir Hossain, and Shivakumar Devaiah. The Formation,Structure and Activity of Phytochemicals. Recent Advances in Phytochemistry,vol 45. Springer, New York, NY. 2015. https://doi.org/10.1007/978-3-319-20397-3_5

7.    Kumar,Dhirendra, Danda Chapagai, Phillip Dean,and Mackenzie Davenport. Biotic and Abiotic Stress Signaling Mediated bySalicylic Acid. In: Pandey G. (eds) Elucidation of Abiotic Stress Signaling in Plants. Springer,New York, NY.2015 https://doi.org/10.1007/978-1-4939-2211-6_12